Table 2.

Percentage of early- and late-apoptotic/necrotic IGROV1 cells after treatment with MK1775 and ¹⁷⁷Lu-DOTA-chCE7

IGROV1	Untreated control	MK1775 [300 nM]	177Lu-DOTA-chCE7 [5.0 MBq/ml]	Combined treatment
Early-apoptosis	4% ± 1	8% ± 2	29% ± 10	40% ± 4
Late-apoptosis/necrosis	9% ± 2	10% ± 2	13% ± 2	12% ± 1

The data were generated from three independent flow cytometry experiments